Tamer, F. 2020. Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count. CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.3 , 229-232.

Tamer, F., (2020). Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count. CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.3, 229-232.

Tamer, FUNDA. "Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count," CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.3, 229-232, 2020

Tamer, FUNDA. "Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count." CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.3, pp.229-232, 2020

Tamer, F. (2020) . "Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count." CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.3, pp.229-232.

@article{article, author={FUNDA TAMER}, title={Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count}, journal={CUTANEOUS AND OCULAR TOXICOLOGY}, year=2020, pages={229-232} }